Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Diuretics in Kidney Disease
NCT04542304 · Stanford University · PHASE2 · terminated · last registry update 2025-06-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of resources” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-08Also stopped (terminated): University of Alberta, Furosemide + Chlorthalidone (NCT05915286)
- 2026-03-13Phase 3 first posted: Hospital de Clinicas de Porto Alegre, Furosemide 40 Milligrams. + Furosemide 40 Milligrams. (NCT07469722)
- 2026-01-13Also stopped (terminated): University of California, San Francisco, Anti-hypertensive agent: amlodipine + Anti-hypertensive agent: Chlorthalidone (NCT05370599)
- 2025-12-08Also stopped (withdrawn): EMS, Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg + Olmesartan medoxomil 20mg + Chlortalidone 25mg (NCT02493322)
- 2025-12-08Also stopped (withdrawn): EMS, Olmesartan medoxomil 40mg + chlorthalidone 12,5mg + Olmesartan medoxomil 40mg + chlorthalidone 25mg (NCT02483936)
- 2025-11-18Phase 3 first posted: Yan Li, a drug against SLC12A3 (NCT07232966)
- 2025-08-12Phase 3 first posted: Kyungdong Pharmaceutical Co., Ltd., KDF1901-R0 + KDF1901-L (NCT07116863)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
- 2025-07-29Results posted on the registry: Prevencion, Hydrochlorothiazide + Amlodipine (NCT02373163)
- 2025-07-22Results posted on the registry: University of Alabama at Birmingham, Perindopril + Losartan (NCT03295734)
- 2025-07-09Results posted on the registry: Alnylam Pharmaceuticals, Indapamide + Amlodipine (NCT05103332)
- 2025-06-12Results posted on the registry: Eurofarma Laboratorios S.A., Chlorthalidone 25 mg + amiloride hydrochloride 5 mg + Higroton® Laboratório Novartis (NCT01191450)
- 2025-06-03Results posted on the registry: George Medicines PTY Limited, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg + telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg (NCT04518293)
- 2025-06-03Results posted on the registry: George Medicines PTY Limited, Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg + Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (NCT04518306)
- 2025-03-21Results posted on the registry: Pfizer, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris + Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma. (NCT06205407)
- 2025-02-14Also stopped (terminated): Stadtspital Zürich, Furosemide + Metolazone (NCT05986773)
- 2024-10-10Results posted on the registry: University of New Mexico, Treatment of Furosemide + Hydrochlorothiazide + Treatment of Furosemide + Metolazone (NCT00690521)
- 2024-07-29Results posted on the registry: University of Iowa, Clonidine Pill + Hydrochlorothiazide (NCT03109795)
- 2024-07-29Also stopped (terminated): University of Iowa, Clonidine Pill + Hydrochlorothiazide (NCT03109795)
- 2024-07-15Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., Allisartan Isoproxil/Sustained-Release Indapamide + Allisartan Isoproxil (NCT06500689)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision